Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate: A case report

Acta Urologica Japonica

Volumn 60, Issue 1, 2014, Pages 39-43

  Kimura, Hiroko ^a   Uegaki, Masayuki ^a   Aoyama, Teruyoshi ^a   Kawai, Jun ^a   Hamano, Toshiaki ^a   Hashimura, Takayuki ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Chemotherapy; Prostate; Small cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; DRUG DERIVATIVE; ENOLASE; IRINOTECAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD; CASE REPORT; CREUTZFELDT JAKOB DISEASE; FATALITY; HUMAN; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METASTASIS; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SMALL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; CREUTZFELDT-JAKOB SYNDROME; FATAL OUTCOME; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; PHOSPHOPYRUVATE HYDRATASE; PROSTATE; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894641012     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Palmgren JS, Karavadia SS and Wakefield MR: Unusual and underappreciated: small cell carcinoma of the prostate. Scmin Oncol 34: 22-29, 2007
2. Oesterling JE, Hauzeur CG and Farrow GM: Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 147: 804-807, 1992
3. Smith DC, Tucker JA and Trump DL: Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol 10: 499-505, 1992
4. Culine S, El Demery M, Lamy PJ, et al: Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178: 844-848, 2007
5. Fukuoka M, Furuse K, Saijo N., et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855-861, 1991
6. Noda K, Nishiwaki Y, Kawahara M., et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
7. Schmittel A, Sebastian M, Fischer von Weikersthal L, et al.: A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22: 1798-1804, 2011
8. Hermes A, Bergman B, Bremnes R., et al.: Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 26: 4261-4267, 2008
9. Lara PN J.r., Natale R, Crowley J., et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27: 2530-2535, 2009
10. Yamada T, Ohtsubo K, Mouri H., et al.: Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Int J Clin Oncol 14: 468-472, 2009
11. Abbas F, Civantos F, Benedetto P., et al.: Small cell carcinoma of the bladder and prostate. Urology 46: 617-630, 1995